Patents Examined by Shengjun Wang
  • Mixtures of sabadilla alkaloids and azadirachtin and uses thereof
    Patent number: 11278028
    Abstract: The present invention is directed to pesticidal mixtures comprising sabadilla alkaloids and azadirachtin and methods of controlling pests including insects and mites by application of pesticidal mixtures comprising sabadilla alkaloids and azadirachtin.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: March 22, 2022
    Assignee: McLaughlin Gormley King Company
    Inventors: Robert A. Suranyi, Donald L. Sundquist
  • Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene
    Patent number: 11273137
    Abstract: The invention provides methods for treating or preventing developmental disorders associated with mutations in the OCD1 gene.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: March 15, 2022
    Assignees: Board of Trustees of Michigan State University, Spectrum Health Innovations LLC
    Inventors: Andre Bachmann, Caleb Bupp, Surender Rajasekaran
  • Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration
    Patent number: 11266658
    Abstract: The present disclosure relates to an orally administered pharmaceutical formulation containing an inclusion complex formed as varenicline or a pharmaceutically acceptable salt thereof is included in cyclodextrin. The pharmaceutical formulation can improve convenience of medication by effectively masking the bitter taste of the drug and the irritation during swallowing, can provide the oxidation stability of varenicline and can improve the solubility of the drug.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 8, 2022
    Assignee: CTC BIO, INC.
    Inventors: Hong Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Seul Ki Meang, Su-Jun Park, Seong-Shin Kwak
  • Methods of treatment of viral infection and uses of anti-HSC70 inhibitors
    Patent number: 11266675
    Abstract: There are disclosed methods of treatment of viral infection. The method makes use of administration of an anti-Hsc70 inhibitor. There are also disclosed uses of anti-Hsc70 inhibitor.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: March 8, 2022
    Assignee: CITY UNIVERSITY OF HONG KONG
    Inventor: Ming-liang He
  • Method for increasing cell proliferation in pancreatic beta cells, treatment method, and composition
    Patent number: 11266647
    Abstract: The present invention relates to a method of increasing cell proliferation in a population of pancreatic beta cells and a method of treating a subject for a condition associated with an insufficient level of insulin secretion. Also disclosed is a composition. The composition includes a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1 A) inhibitor and a transforming growth factor beta (TGFP) superfamily signaling pathway inhibitor.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: March 8, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Andrew F. Stewart, Peng Wang
  • Pharmaceutical composition for preventing and treating diabetic nephropaphy including adenosine derivative
    Patent number: 11266644
    Abstract: A pharmaceutical composition for preventing or treating diabetic nephropathy is provided. According to the present invention, a pharmaceutical composition for preventing or treating diabetic nephropathy comprises an adenosine derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: March 8, 2022
    Assignee: FUTURE MEDICINE CO., LTD.
    Inventors: Hea Ok Kim, Chong-Woo Park, Mi Ra Yu, Bo Mi Park
  • Maslinic and oleanolic acids derivatives for treating SARS-CoV-2 infection
    Patent number: 11266632
    Abstract: Provided are methods of using oleanolic acid and derivatives for treating coronavirus infection. The method includes using propargyl-moiety containing oleanolic acid derivatives for inhibiting coronavirus growth by impairing the viral replication of SARS-CoV-2 through inhibition of the viral function of SARS-CoV-2 main protease.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: March 8, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Raya Soltane, Hani Abdullah Alhadrami, Ahlam Alasiri, Hichem Ben Jannet, Karim Chouaib, Amani Chrouda, Ahmed Mostafa, Rami Adel Pashameah
  • Dihydropyrimidine compounds and uses thereof in medicine
    Patent number: 11261190
    Abstract: A dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B, specifically, is a compound having Formula (I) or (Ia), or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification; and also includes the use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: March 1, 2022
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinchang Liu, Qingyun Ren, Guanghua Yan, Siegfried Goldmann, Yingjun Zhang
  • Benzodiazepine derivatives as RSV inhibitors
    Patent number: 11254664
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: February 22, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
  • Method and composition for inhibiting virus infection
    Patent number: 11253527
    Abstract: The present invention pertains to a composition for preparing a medicament for preventing and/or treating a virus infection, especially a hepatitis B virus infection and/or a herpes simplex virus, and uses thereof.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: February 22, 2022
    Assignee: ARJIL BIOTECH HOLDING COMPANY LIMITED
    Inventors: Yeh B Wu, Jir-Mehng Lo, Hui Ju Liang, Pei-Hsin Lin, Cheng Huang
  • Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
    Patent number: 11246873
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: February 15, 2022
    Assignee: The Scripps Research Institute
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Ozonides for treating or preventing virus infections
    Patent number: 11246854
    Abstract: Described are methods of treating or preventing a virus in a subject comprising administering ozonides to the subject.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: February 15, 2022
    Assignees: THE JOHNS HOPKINS UNIVERSITY, UNIVERSITY OF NEBRASKA MEDICAL CENTER
    Inventors: Ravit Boger, Jonathan Vennerstrom
  • Methods of treating multiple sclerosis
    Patent number: 11246850
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: February 15, 2022
    Assignee: Biogen MA Inc.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine
    Patent number: 11247998
    Abstract: The present invention relates to a piperazine heteroaryl derivative, a preparation method therefor and the use of same in medicine. In particular, the present invention relates to the piperazine heteroaryl derivative as shown in the general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and the use of same as a capsid protein inhibitor, in particular in the prevention and/or treatment of diseases such as hepatitis B, influenza, herpes, AIDS, etc. The definitions of each group in the general formula (I) are the same as those defined in the description.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: February 15, 2022
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Xin Li, Wei He, Yang Chen, Feng He, Weikang Tao
  • Formulations of lixivaptan for the treatment of polycystic disease
    Patent number: 11241441
    Abstract: Formulations of lixivaptan, and methods of using the same, are provided for the treatment of polycystic disease.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: February 8, 2022
    Assignee: PALLADIO BIOSCIENCES, INC.
    Inventor: Lorenzo Pellegrini
  • EBNA1 inhibitors and their method of use
    Patent number: 11242317
    Abstract: Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: February 8, 2022
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Venkata Velvadapu
  • Antiviral therapy
    Patent number: 11234985
    Abstract: The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: February 1, 2022
    Inventor: Mark Richard Underwood
  • Methods for treating cryptosporidiosis using triazolopyridazines
    Patent number: 11229649
    Abstract: Methods for treating or prophylaxis of a cryptosporidium infection using compositions comprising a structure disclosed herein. Also provided are pharmaceutical compositions and kits for alleviating the symptoms of, for treating, or for preventing the occurrence of cryptosporidium infection. The kits comprise one or more compounds having a structure disclosed herein, such as in an oral composition, and instructions for use, storage, and the like.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: January 25, 2022
    Assignee: University of Vermont and State Agricultural College
    Inventors: Christopher D. Huston, Kovi Bessoff, Rajiv Satish Jumani
  • High concentration formulation
    Patent number: 11213531
    Abstract: The present disclosure provides high concentration formulations of cortexolone-17?-propionate suitable for treating alopecia.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: January 4, 2022
    Assignee: Cassiopea S.P.A.
    Inventor: Luigi Maria Longo
  • Agents for reversing toxic proteinopathies
    Patent number: 11207278
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: December 28, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Anna Greka, Moran Dvela-Levitt, Maria Alimova, Eric Lander, Todd R. Golub, Florence Wagner, Brian Chamberlain, Valeria Padovano, Joseph Growney